.jpeg)
Aurobindo Pharma has said it is expecting its proposed vaccine candidate for COVID-19 to undergo Phase I and II trials by the end of 2020, while Phase III may be undertaken during March-April next year.
Managing Director of Aurobindo Pharma, Narayanan Govindarajan said the vaccine for COVID-19 is being developed by Profectus BioSciences Inc in the U.S., which was acquired by AurobindoPharma's subsidiary Auro Vaccines LLC. "So on the VSV platform, they (Auro Vaccines) are already developing a COVID-19 vaccine as well and we are creating the capacity in India wherein there are two phases of capacity. The first set of capacity would be ready by October, where we would like to make the product and start the Phase-I and Phase-II by the end of the year.”
“And our commercial facility, we are aiming to get it ready by around March-April timeline where we would like to make the product for even the Phase III trials. That is the timeline for the COVID-19 vaccine based on our current assumptions,” Mr. Govindarajan said.
Aurobindo Pharma has said it is expecting its proposed vaccine candidate for COVID-19 to undergo Phase I and II trials by the end of 2020, while Phase III may be undertaken during March-April next year.
Managing Director of Aurobindo Pharma, Narayanan Govindarajan said the vaccine for COVID-19 is being developed by Profectus BioSciences Inc in the U.S., which was acquired by AurobindoPharma's subsidiary Auro Vaccines LLC. "So on the VSV platform, they (Auro Vaccines) are already developing a COVID-19 vaccine as well and we are creating the capacity in India wherein there are two phases of capacity. The first set of capacity would be ready by October, where we would like to make the product and start the Phase-I and Phase-II by the end of the year.”
“And our commercial facility, we are aiming to get it ready by around March-April timeline where we would like to make the product for even the Phase III trials. That is the timeline for the COVID-19 vaccine based on our current assumptions,” Mr. Govindarajan said.
139.jpeg)
260.jpeg)
259.jpeg)
258.jpeg)
